Your browser doesn't support javascript.
loading
Mitochondrial targeted doxorubicin derivatives delivered by ROS-responsive nanocarriers to breast tumor for overcoming of multidrug resistance.
Zhong, Xin-Cheng; Shi, Ming-Han; Liu, Hui-Na; Chen, Jie-Jian; Wang, Tian-Tian; Lin, Meng-Ting; Zhang, Zhen-Tao; Zhou, Yi; Lu, Yi-Ying; Xu, Wen-Hong; Gao, Jian-Qing; Xu, Dong-Hang; Han, Min; Chen, Yi-Ding.
Afiliação
  • Zhong XC; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
  • Shi MH; Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
  • Liu HN; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
  • Chen JJ; Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
  • Wang TT; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
  • Lin MT; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
  • Zhang ZT; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
  • Zhou Y; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
  • Lu YY; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
  • Xu WH; Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
  • Gao JQ; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
  • Xu DH; Department of Pharmacy, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic China.
  • Han M; Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
  • Chen YD; Department of Breast Surgery, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic China.
Pharm Dev Technol ; 26(1): 21-29, 2021 Jan.
Article em En | MEDLINE | ID: mdl-33070673
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Doxorrubicina / Espécies Reativas de Oxigênio / Resistência a Múltiplos Medicamentos / Nanopartículas / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Doxorrubicina / Espécies Reativas de Oxigênio / Resistência a Múltiplos Medicamentos / Nanopartículas / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article